0.48
+0.0882(+22.63%)
Currency In USD
Address
130 West 42nd Street
New York City, NY 10036
United States of America
Phone
877 746 4891
Website
Sector
Healthcare
Industry
Biotechnology
Employees
12
First IPO Date
June 11, 2015
| Name | Title | Pay | Year Born |
| Mr. David W. Nassif J.D. | Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer, General Counsel & Director | 699,519 | 1954 |
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.